Baptist Health South Florida Selects Cota, Inc. to Advance Personalized Cancer Treatment and Research

Miami Cancer Institute at Baptist Health will leverage Cota&rsquo;s data, nodal address and analytics to deliver precision medicine and enable the best treatments at the highest quality of care for patients<br /> &nbsp;

Miami Cancer Institute is improving patient access to the latest and most effective cancer treatment advances through its role in the Memorial Sloan Kettering Cancer Alliance (MSK). The Institute offers leading clinical cancer services, cutting-edge technology and a superior patient experience, in addition to leveraging Cota’s market-leading Provider Solution to identify unwarranted variances at the physician and practice-level. Cota recently announced a multi-year partnership with MSK with the goal of improving patient care, advancing world-class research efforts and reducing the total cost of oncology care with actionable data and analytical insights.

The Cota Provider solution is an end-to-end oncology analytics suite comprised of real-world analytics, decision support and value based tracking. Leveraging the patented Cota Nodal AddressTM(CNA), a precision patient classification system, and Cota Real-World Evidence (RWE), the industry’s leading collection of oncology patient data, the Cota Provider solution improves quality and outcomes in cancer care, increases oncology margins in fee-for-service and value-based arrangements and assists practices looking to transition to value-based care.

“Miami Cancer Institute is committed to combining the latest technology and innovation to enable personalized medicine in cancer care. That is why we selected Cota, a market leader in data and analytics. By using their Provider Solution and CNA we’ll be able to generate critical insights from our data to continually improve the quality of care we deliver to our patients,” said Michael J. Zinner, MD, founding chief executive officer and executive medical director of Miami Cancer Institute.

“With the ability to see genomic-level data alongside cost and historical clinical data, Cota will help accelerate our journey to value-based care,” said Leonard Kalman, MD, executive deputy director and chief medical officer of Miami Cancer Institute. “This not only increases the level of precision in our patients’ treatment journey, but it also ensures that every individual receives the highest quality of care possible which increases the odds of survivorship.”

Miami Cancer Institute is the third member of the MSK Cancer Alliance, a transformative initiative that enhances the quality of cancer care and the lives of cancer patients by bringing Memorial Sloan Kettering Cancer Center’s standards of care, state-of-the-art treatments and clinical trials to the community cancer center setting. This meaningful partnership will further augment Miami Cancer Institute’s position as the primary destination for cancer patients in the southeastern United States, Latin America and the Caribbean.

"The benefits of leveraging the CNA will result in reducing unwarranted variation in treatments, costs and outcomes and lead to treatment standardization and notable operational improvement on a practice and physician level, setting Miami Cancer Institute apart from other providers," said Andrew Norden, MD, chief medical officer at Cota. “The use of Cota through the lens of the CNA enables physicians and other health care professionals to deliver care resulting in optimal clinical outcomes for every individual patient and to reduce the total cost of care for the population being served.“